Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

2.0K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.0K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Introduction to Hemostasis01:05

Introduction to Hemostasis

13.2K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
13.2K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

11.9K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.9K
Blood Transfusion01:15

Blood Transfusion

2.1K
Blood transfusion is a critical medical procedure that saves lives and treats various medical conditions. It involves transferring blood from a donor to a recipient. This process requires a thorough understanding of the ABO blood group system and its associated antigens and antibodies.
Blood Transfusion Overview
A blood transfusion is a medical procedure used to replace blood lost due to injury, surgery, or to treat conditions such as anemia or cancer. During a transfusion, donor blood is...
2.1K
Rh Blood Group01:19

Rh Blood Group

2.7K
The Rhesus (Rh) antigen is crucial in determining blood groups and ensuring compatibility during blood transfusions.
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Short-term emicizumab in patients with acquired hemophilia A.

Haematologica·2026
Same author

Machine Learning-Based Prediction of Antimicrobial Resistance in <i>Escherichia coli</i> from MALDI-TOF Mass Spectrometry Data.

Diagnostics (Basel, Switzerland)·2026
Same author

Normalization of Haemostasis in People with Haemophilia A: Expert Consensus on Unmet Needs and a Framework for Advancing Towards Health Equity.

TH open : companion journal to thrombosis and haemostasis·2026
Same author

Heterogeneity Among Plasma-Derived von Willebrand Factor Concentrates: Implications for Comparative Effectiveness Analyses.

Seminars in thrombosis and hemostasis·2026
Same author

Forgotten Steps in the Coagulation Cascade.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same author

Thrombin Generation as a Potential Surrogate Marker of Hemostatic Status in the Era of Novel Therapies for Hemophilia.

Thrombosis and haemostasis·2026

Related Experiment Video

Updated: Jan 11, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.2K

Normalization in hemophilia: conceptual foundations and clinical implications.

Kazimieras Maneikis1, Evelien Krumb2, Cedric Hermans2

  • 1Clinic of Hematology and Oncology, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.

Research and Practice in Thrombosis and Haemostasis
|November 10, 2025
PubMed
Summary

Hemophilia treatments are advancing, aiming for "normalized" lives for patients. Defining optimal hemostasis and addressing psychosocial needs are crucial for achieving this goal.

Keywords:
disease burdenhemophiliahemostasisnormalizationtreatment expectations

More Related Videos

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

14.3K
Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro
10:25

Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro

Published on: March 19, 2016

9.9K

Related Experiment Videos

Last Updated: Jan 11, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.2K
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

14.3K
Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro
10:25

Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro

Published on: March 19, 2016

9.9K

Area of Science:

  • Hematology
  • Genetics
  • Patient Quality of Life

Background:

  • Hemophilia is an inherited bleeding disorder caused by clotting factor deficiency, leading to significant morbidity and reduced quality of life.
  • Recent therapeutic advancements have improved disease management, reduced complications, and expanded care access for individuals with hemophilia.
  • Current treatment goals are evolving towards achieving a 'normalized' life for patients, enhancing well-being and health equity.

Purpose of the Study:

  • To define optimal and achievable levels of hemostasis normalization with current and emerging hemophilia therapies.
  • To emphasize the importance of 'life normalization' alongside hemostasis normalization, addressing psychosocial impacts and treatment burden.
  • To highlight the need for novel outcome assessment tools beyond traditional bleeding rates.

Main Methods:

  • Review of current advancements in hemophilia treatment and care.
  • Analysis of the concept of 'normalization' in the context of hemophilia management.
  • Discussion on the limitations of traditional outcome metrics and the need for new assessment tools.

Main Results:

  • The pursuit of normalized hemostasis and life is a promising new goal in hemophilia care.
  • Achieving normalization requires a clear definition of optimal hemostasis and consideration of psychosocial factors.
  • Existing outcome measures may be insufficient for evaluating the superiority of novel hemophilia therapies.

Conclusions:

  • Striving for normalized lives for hemophilia patients is achievable and desirable, enhancing quality of life and health equity.
  • A comprehensive approach integrating hemostasis normalization with life normalization, including mental well-being, is essential.
  • Careful consideration of potential risks and specific needs of all affected individuals, including carriers and women/girls, is necessary.